Tumour necrosis factor receptor II (p75) signalling is required for the migration of Langerhans' cells

被引:83
|
作者
Wang, B
Kondo, S
Shivji, GM
Fujisawa, H
Mak, TW
Sauder, DN
机构
[1] UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV DERMATOL,TORONTO,ON M4N 3M5,CANADA
[2] AMGEN INST,TORONTO,ON,CANADA
关键词
D O I
10.1111/j.1365-2567.1996.tb00016.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Langerhans' cells (LC) represent the major antigen-presenting cells within the epidermis. Following exposure of the skin to antigen, LC take up antigen, migrate into draining lymph nodes (DLN) and present processed antigen to T lymphocytes, thereby initiating an immune response. The molecular mechanisms responsible for LC migration remain unclear. Cytokines, in particular tumour necrosis factor-alpha (TNF-alpha) have been suggested to influence LC migration. There are two distinct membrane receptors for TNF-alpha, TNF receptor I (TNF-R1, p55) and TNF receptor II (TNF-R2, p75), thought to be responsible for distinct TNF-alpha activities. It is believed that most of TNF biological activities are mediated via TNF-R1. In order to examine the role of TNF-R1 signalling in LC migration, we utilized TNF-R1 gene-targeted mutant mice, Following application of the hapten fluorescein isothiocyanate (FITC), FITC-bearing cells in DLN were examined by flow cytometry. A normal number of FITC+/Ia(+) cells (LC) were found in DLN from TNF-R1-deficiency mice, suggesting that TNF-R1-dependent signalling is not crucial for LC migration. To investigate the possibility of signalling through TNF-R2, blocking studies using a neutralizing anti-TNF-alpha antibody were performed. The results revealed that anti-TNF-alpha antibody significantly inhibited LC accumulation in DLN in TNF-R1-deficient mice, thus suggesting that TNF-R2 signalling is involved in LC migration from skin to DLN and that murine LC express TNF-R2.
引用
收藏
页码:284 / 288
页数:5
相关论文
共 50 条
  • [21] p75 Neurotrophin receptor is required for glioma invasion and proliferation
    Kenchappa, Rajappa S.
    Valadez, J. Gerardo
    Carter, Bruce D.
    Cooper, Michael K.
    Forsyth, Peter A.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 : S17 - S17
  • [22] P75 NEUROTROPHIN RECEPTOR IS REQUIRED FOR GLIOMA INVASION AND PROLIFERATION
    Kenchappa, Rajappa S.
    Valadez, J. Gerardo
    Cooper, Michael K.
    Carter, Bruce D.
    Forsyth, Peter A.
    NEURO-ONCOLOGY, 2012, 14 : 16 - 16
  • [23] The p75 receptor is required for BDNF-induced differentiation of neural precursor cells
    Hosomi, S
    Yamashita, T
    Aoki, M
    Tohyama, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 301 (04) : 1011 - 1015
  • [24] Tumor necrosis factor alpha (TNFα) and its soluble receptor p75 (sTNF-R p75) in familial combined hyperlipidemia (FCHL)
    Cavallo, MG
    Montali, A
    Monetini, L
    Valente, L
    Mariani, P
    Bifolco, M
    Sirinian, MI
    Antonini, TM
    Fioretti, F
    Campagna, F
    Verna, R
    Arca, M
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2005, 15 (04) : 262 - 269
  • [25] Serum p75 tumour necrosis factor receptor and interleukin-12 in patients with juvenile idiopathic arthritis and systemic lupus erythematosus
    Mihaylova, D.
    Lisichky, K.
    Telcharova, A.
    Stefanov, S.
    Boneva, P.
    Mihaylova, A.
    Naumova, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 559 - 560
  • [26] Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA
    Neuner, P
    Pourmojib, M
    Klosner, G
    Trautinger, F
    Knobler, R
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 1996, 288 (11) : 691 - 696
  • [27] Serum p75 tumour necrosis factor receptor as marker of disease activity in juvenile idiopathic arthritis and systemic lupus erythematosus in children
    Mihaylova, D.
    Lisitchky, K.
    Stefanov, S. T.
    Telcharova, A.
    Mihaylova, A.
    Naumova, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 444 - 445
  • [28] A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome
    Maciejewski, JP
    Ristiano, AM
    Sloand, EM
    Wisch, L
    Geller, N
    Barrett, JA
    Young, NS
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) : 119 - 126
  • [29] DUAL ROLE OF THE P75 TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR IN TNF CYTOTOXICITY
    BIGDA, J
    BELETSKY, I
    BRAKEBUSCH, C
    VARFOLOMEEV, Y
    ENGELMANN, H
    BIGDA, J
    HOLTMANN, H
    WALLACH, D
    JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (02): : 445 - 460
  • [30] Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients
    Opala, T
    Rzymski, P
    Wilczak, M
    Wozniak, J
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2005, 26 (01) : 43 - 46